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Abstract
Background: Opioid maintenance treatment with methadone is regarded as gold standard in the therapy of
opioid dependence. Identification of the ‘right’ methadone dose, however, remains challenging. We wanted to
explore if the Opiate Dosage Adequacy Scale (ODAS) is a helpful instrument in methadone titration.
Methods: Within this 12-months prospective naturalistic cohort study patients in stable maintenance treatment
with methadone (Eptadone®) were included. Sociodemographic and clinical data were gathered at baseline, and
months 3, 6, and 12. At the same points in time, the instruments ODAS, European Addiction Severity Index
(EuropASI), and Derogatis Interview for Sexual Functioning-Self Report (DISF-SR) were applied.
Results: Five hundred fifteen patients were enrolled, 129 patients prematurely terminated substitution treatment
(treatment failure), in 108 patients substitution medication was changed, likely due to bitter taste of Eptadone®.
Complete longitudinal ODAS and EuropASI data sets were available for 229 patients. The frequency of adequate
methadone doses (ODAS) increased (60.9 % at baseline, 85.3 % at month 12) as well as the average daily
methadone dose (63.8 (±30.8) mg/day at baseline to 69.6 (±36.0) mg/day at month 12). Inadequacy of methadone
dose was not associated with treatment failure (RR 1.019; CI 95 % 0.756–1.374). Addiction severity decreased
statistically significantly. Compared to adequately dosed patients, inadequately dosed patients benefited more, in
that they showed greater improvements in ODAS scores, had higher increases in methadone dose, and partially
experienced more advanced sexual functioning.
Conclusion: Application of ODAS was associated with improved methadone dose adequacy and addiction severity
parameters as well as increased methadone doses. Its usefulness should be corroborated in a controlled trial.
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Background
Dependence on illegal opioids is a severe chronic illness,
which is associated with relevant increased morbidity,
functional impairments, social disintegration and prema-
ture mortality [1–3]. Opioid maintenance treatment
(OMT) comprises the replacement of an illegal opioid
by a prescribed opioid, favorably with good μ-receptor
activity and longer half-life to avoid euphoric and with-
drawal symptoms. OMT reduces mortality, illicit drug
use, frequency of injecting, HIV-transmission, and crim-
inal activity whilst improving social integration [1, 3–6].
Methadone and buprenorphine represent the medica-
tions most commonly used in OMT, and both have
widely proven effectiveness. Methadone seems to have
some advantages in terms of treatment retention when
doses are in the range of 60–100 mg per day [7, 8].
Aside from the absolute methadone dose, also the per-
ception of dose inadequacy can lead to treatment non-
adherence [9]. Consequently, an absolute methadone
dose cannot serve as a sole indicator of sufficiency and
should be related to clinical and patient reported param-
eters. In this context, Trujols and colleagues suggested
distinguishing between the concepts holding dose, dose
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adequacy, satisfaction with methadone as a medication,
and satisfaction with treatment [10]. The latter two di-
mensions represent subjective phenomena, while the
first two constructs include subjective and objective phe-
nomena, with dose adequacy as a construct that can be
measured by a validated instrument, the Opiate Dose
Adequacy Scale (ODAS) [11, 12]. An adequate dose is
defined as the amount of methadone, which allows the
patient (a) to abstain from heroin use or only use heroin
occasionally, (b) not to experience continuous opioid
withdrawal or only mild withdrawal symptoms, (c) not
to experience frequent episodes of heroin craving or
only mild episodes, (d) in case of heroin use, to experi-
ence no or little effect of heroin (cross-tolerance), and
(e) not to show signs and symptoms of overmedication
or only to a very small extent [10]. Compared to ad-
equate doses, sub-therapeutic doses (<40 mg methadone
per day) are associated with more severe symptoms in
aforementioned dimensions.
Scientific literature and scientifically based medical
guidelines (i.e. World Health Organization) do not rec-
ommend to initiate OMT with a primary abstinence goal
(maintenance to abstinence), however, the German Phys-
ician Chamber and treatment regulations (Narcotics Act,
Betäubungsmittelverschreibungsverordnung, BtMVV) still
regard abstinence as a core target [13–15]. Consequently,
a relevant number of German physicians deliver OMT
with high abstinence orientation and lower substitution
doses, despite the fact that stable abstinence is a rare
outcome [16]. In a large German longitudinal clinical-
epidemiological study over 6 years in around 2700
substituted patients average daily substitution doses were
around 75 mg for d,l-methadone, 55 mg for l-methadone,
and 7 mg for buprenorphine, around 40 % of patients re-
ceived methadone doses < 60 mg per day [17].
To examine dose adequacy in OMT in Germany, the
present study was conducted. Baseline data are reported
elsewhere and point to high frequencies of inadequate
dosing (40 % of the sample) according to ODAS [18].
On average, patients with inadequate doses received
higher doses (70.6 (±33.0) mg methadone per day) com-
pared to adequately dosed patients (57.8 (±27.5) mg
methadone per day) and suffered from a more pro-
nounced addiction severity according to the European
Addiction Severity Index (EuropASI) [18]. In this con-
text, an instrument like ODAS could serve as a reliable
tool to guide healthcare providers and patients to iden-
tify a methadone dose, which meets the individual’s
needs. Analyses of longitudinal data aimed to explore
whether inadequate dosing leads to treatment drop-out,
how dose adequacy is associated with treatment out-
come in general, and whether frequencies of inadequate
dosing, addiction severity or sexual functioning changed
over time. We hypothesized, that inadequate dosing
leads to increased treatment drop-out, that addiction se-
verity improves over time, and that sexual dysfunction is
more pronounced in adequately dosed patients. Finally
we wanted to explore, whether the use of ODAS could
be associated with increased frequencies of adequate
dosing.
Methods
Within an observational, prospective cohort study (Pro-
spective observational study to assess the efficacy and
tolerability of Eptadone® in heroin addicted patients under-
going a methadone maintenance treatment, METHO.DE
study), 14 experienced substitution centres in Germany
consecutively recruited patients with opioid dependence
(F11.2) according to the International Classification of
Diseases-10 (ICD-10) (International Classification of Men-
tal Disorders, 2010). Further inclusion criteria comprised
age 18 or older, maintenance treatment with methadone
(Eptadone®) at least 1 month prior to study entry and
signed informed consent Methadone was administered
once daily orally. Patients were excluded from study entry
in case of inability to follow the study plan, decompen-
sated mental disorders, non drug-related epileptic seizures
and acute or severe somatic diseases. Over the one-year
study period, visits were scheduled at baseline (t0),
3 months (t1), 6 months (t2), and 12 months (t3). The
baseline visit included a complete medical anamnesis and
physical examination, as well as recording of routine la-
boratory testing if it was performed within 2 months prior
the baseline visit. Additionally, all visits comprised the
European Addiction Severity Index (EuropASI), the Opi-
ate Dosage Adequacy Scale (ODAS), and the Derogatis
Interview for Sexual Functioning-Self Report (DISF-SR).
These diagnostic instruments were handed out by a nurse
specialist. Patients filled out the instruments in a secluded
room during waiting time.
The EuropASI is a validated and reliable instrument
that covers drug use-related consequences in social,
health and legal dimensions (i.e. somatic health, work
and economic situation, alcohol use, legal situation, fam-
ily and relationships, and mental health) [19, 20]. It was
applied by trained interviewers, and reported scores
reflect the interviewer severity ratings. The ODAS is a
validated instrument to measure dose adequacy of
methadone medication in maintenance treatment, which
has been adapted to the German background [11, 12].
ODAS consists of six dimensions and comprises the
areas heroin consumption, narcotic blockade, opiate
withdrawal syndrome mental and somatic, craving for
heroin, and methadone overdosing. Items have to be
filled out either by the physician based on the patient
anamnesis or by the patient himself. Scores range be-
tween 1 (worst) and 5 (best). In this study, patients were
regarded as not adequately dosed, if they reached a score
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of 3 or less in any ODAS dimension at any visit. On the
other hand, patients were considered adequately dosed,
if they reached a score of 4 or higher in every item in
every visit.
For comparative analyses two groups of patients were
formed. Doses were regarded as adequate, if scores of 4
or 5 were yielded in each item in every visit. Patients
were assigned to the inadequate dose group, if their
ODAS score failed to meet adequate dosing threshold at
least once throughout the study. The DISF-SR represents
a validated and reliable 25-item self-report instrument,
which measures sexual functioning in five dimensions (i.e.
sexual cognition/fantasy, sexual arousal, sexual behavior/
experience, orgasm, and sexual drive/relationship) [21].
The study was approved by the ethics committee of
the Physician Chamber Hamburg (Reference PV3468),
Germany, and by all responsible physician chamber eth-
ics committees outside the state of Hamburg. The study
was conducted in accordance with the declaration of
Helsinki. Patients provided informed written consent
and could withdraw from the study at any time without
providing reasons and without negative consequences
Fig. 1 Study flow
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for further treatment. Patients were included in the
study between September 2010 and February 2012.
Data analysis was performed with the SPSS 20 statistical
package. Data is presented in a descriptive way, statistical
analyses were performed to stratify by dose adequacy and
in case of sexual functioning by gender. The Mann—
Whitney test, student t-test, or Chi2-test were used for
analysis of statistical significance. To determine the associ-
ation of dose adequacy, age, and gender, relative risks were
computed. The level of significance was set at p < .05.
Results
Five hundred fifteen patients were enrolled in the study.
Eleven patients withdrew their consent before the base-
line visit. Following relative data are calculated with n =
504 patients participating in the baseline visit as parent
population. Two hundred thirty-two patients (46.0 %)
regularly completed the study with the 12 months (t3)
visit, 129 patients (25.6 %) prematurely terminated sub-
stitution treatment (treatment failure), in 108 patients
(21.4 %) the substitution medication was changed, likely
due to dislike or bitter taste of Eptadone®, and in eight
cases the substitution medication was changed due to
adverse drug reactions. The remaining drop-outs were
due to changed residence, entrance into drug free treat-
ment, or unknown (Fig. 1). In three patients, data for
ODAS and EuropASI were incomplete, consequently
longitudinal data on clinical parameters and ODAS as
well as EuropASI were analyzed in 229 patients. How-
ever, complete data including DISF-SR were available for
160 patients only. At baseline, patients were on average
36.5 (±9.2) years old, three out of four participants were
male, and they were predominantly Caucasian, with high
frequencies being single and living alone, with low for-
mal education and high unemployment rates (Table 1).
According to ODAS, 60.9 % of a total of 504 patients
received adequate methadone doses at baseline, this fre-
quency increased to 81.2 % at t1 (total n = 383), to
84.7 % at t2 (total n = 301), and 85.3 % at t3 (total n =
231). In a similar direction, the average methadone dose
for the whole group increased from 63.8 (±30.8) mg/day
at baseline, to 68.6 (±32.2) mg/day at t1, and 70.2 (±34.1)
mg/day at t2, with a slight decrease at t3 with 69.6
(±36.0) mg/day (Fig. 2). Over time (t0 to t3), adequacy of
methadone dosage increased statistically significant in all
ODAS domains, except methadone overdosing. Increase
was reflected distinctly in the ODAS global score (+1.5
(±2.8), p < .001), and to a smaller extent in the areas her-
oin consumption (+.1 (±.6), p < .001), narcotic blockade
(+.2 (±.7), p < .001), physical opiate withdrawal syndrome
(+.4 (±.1.1), p < .001), mental opiate withdrawal syn-
drome (+.4 (±1.0), p < .001), and craving for heroin (+.4
(±.9), p < .001). Increase of ODAS scores was statistically
significant in both the adequate (global score + .64 (±1.6),
<.001) and the inadequate group (+2.6 (±3.6), p < .001),
however, it was more pronounced in the inadequate
group. Daily methadone dose increased both in the ad-
equate and inadequate group over time, however increase
between t0 and t3 was statistically significant in inad-
equately dosed patients only (+9.5 (±33.9) mg methadone
per day, p = .007; adequate group +2.5 (±20.7) mg metha-
done per day, p = .171) (Fig. 3). The average methadone
dose in the adequate group at t3 was 66.5 (±35.8) mg
methadone per day, in the inadequate group this number
was 87.8 (±31.8) mg methadone per day, frequencies of
patients receiving less than 40 mg methadone per day at
t3 were 28.4 % for the adequate (t0 30.3 %) and 11.8 % for
the inadequate (t0 25.4 %) group (statistically significant at
t3 χ
2 6.485, df = 1, p < .05).
Inadequacy of methadone dosage according to ODAS
was not associated with treatment failure; the relative
risk for patients who were at least once inadequately
dosed to fail in substitution treatment was 1.019 (CI
95 % 0.756–1.374) compared to those, who did not fail.
Likewise, the log rank test for retention in the study by
dose adequacy did not show a statistically significant
Table 1 Baseline sociodemographic characteristics
Average age, years (SD) (n = 515) 36.5 (9.2)
Male gender, % (n = 515) 74.4













Education, % (n = 505)
8–9 years school 63.2
10 years school 23.6
13 years school 5.1
University degree 1.8
Other 6.3
Vocational situation, % (n = 505)
Unemployed 59.0
Employed 34.3
Other (student, homemaker) 6.7
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difference (χ2 .141, df = 1; p = .707). Additional tests ex-
plored the role of age and gender with regards to treat-
ment failure. In this context, being younger than
40 years was associated with a higher risk for treatment
failure (RR 1.68; CI 95 % 1.173–2.410; log rank test χ2
8.512, df = 1; p = .004), whilst gender was not associated
with treatment failure (RR 0.97; CI 95 % 0.693–1.360;
log rank test χ2 0.060, df = 1; p = .807).
Addiction severity according to EuropASI decreased
during study participation, but differed by group. Signifi-
cant reductions in the adequate group were found for
mental health problems (−0.34; ±1.8; p = .033), problems
with psychoactive substances (−.59; ±1.9; p = .001), and
work problems (−.39; ±1.8; p = .012), whereas the areas
relationship problems (−.56; ±2.4; p = .023), problems
with psychoactive substances (−.72; 3.0; p = .018), and
work problems (−.94; ±2.4; p < .001) improved signifi-
cantly in the inadequate group (Fig. 4). Disparities in ad-
diction severity between the adequate and non-adequate
group with statistically stronger problem load in all
EuropASI domains in the inadequate group at baseline
(t0), resolved during study participation.
Sexual functioning improved in men and women over
time (t0–t3), but failed to reach statistical significance,
except for sexual cognition/fantasies (−2.5 (±11.9), p =
.026) and sexual drive in men (−1.6 (±5.9), p = .005). The
subgroup analysis revealed no statistically significant im-
provements in adequately dosed patients. However the
domain sexual drive improved in inadequately dosed men
(−2.0 (±6.1), p = .032) and sexual behavior/experience
improved in inadequately dosed women (−3.6 (±5.2),
p = .007).
Fig. 3 Changes in methadone dose and ODAS total score between baseline (t0) and 12 months (t3) by adequacy group
Fig. 2 Frequency of adequate methadone dose (ODAS) and average methadone dose by time (t0: baseline, t1: 3 months, t2: 6 months, t3: 12 months)
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Discussion
This prospective cohort study examined retention, dose-
adequacy, addiction severity, and sexual functioning
within a 12-months opioid maintenance treatment in
more than 500 patients in experienced German substitu-
tion centres. OMT failed in 25.6 % of patients, another
relatively high proportion of patients (21.4 %) dropped
out from the study due to change of the substitution
medication, but remained in OMT. In this context, it is
noteworthy, that the reported bitter taste of Eptadone®
contributed substantially to the demand for a medication
switch. Formulation of drugs, especially for long-term
treatment, influences adherence and should be consid-
ered in OMT [22].
Overall, the treatment retention rate in our study is
comparable to retention rates of OMT in Germany, which
are around 75 % after 1 year. German retentions rates are
at the upper end of the international span, which ranges
between 22.7 % at 6 months in Iran and 79.6 % at
13 months in Israel [23–25]. High retention rates in
Germany may be regarded as an indicator for good quality
delivery of OMT. Contrary, a surprisingly high number of
patients was inadequately dosed upon study entry. Abstin-
ence orientation in German opioid substitution regulations
may contribute to restrained dosing [16, 26, 27]. However,
inadequate methadone doses according to ODAS at base-
line did not go along with premature treatment drop-out.
This finding is not in line with corroborated study data
Fig. 4 Changes between baseline (t0) and 12 months (t3) in EuropASI score
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[7, 8]. We assume that assessment with ODAS led to a
better consideration of patients’ needs which is reflected
in increased methadone doses and increased frequencies
of adequate dosing. Patients may have remained in OMT,
because they were aware that their concerns were taken
into account. On the health care providers’ side, applica-
tion of ODAS may have paved way for a dose increase, as
this need was documented by a standardized inventory.
Treatment effectiveness is also reflected by improve-
ments in addiction severity, which was more pronounced
in the group of inadequately dosed patients. Due to a
more sufficient methadone dose, we expected stronger ad-
diction severity improvements in adequately dosed pa-
tients. However, more pronounced addiction severity in
inadequately dosed patients at baseline together with
more intense methadone dose adaptions may have con-
tributed to stronger improvements of addiction severity in
inadequately dosed patients [18]. This finding is relevant
for clinical practice, as it shows, that inadequately dosed
patients may derive relevant benefit from dose adapta-
tions. Increased adherence associated with adequate dos-
ing might act as intermediary to improved functional
outcomes [9]. It is noteworthy that, in inadequately dosed
patients, work problems improved the most, followed by
problems with psychoactive substances. This finding un-
derlines the importance of OMT in social rehabilitation
[3]. On the other hand, increased alcohol problems in in-
adequately dosed patients are of concern and call for an
integrative addiction treatment approach, which takes the
variety of substances consumed into account.
Higher methadone doses have been associated with
sexual dysfunction [28]. We did not find a positive asso-
ciation between methadone dose and sexual dysfunction.
On the contrary, sexual function improved statistically
(although not significantly) during study participation
with increasing methadone doses. Considering the im-
provements of the drug use problem and overall life
situation (EuropASI), we assume that general health and
psychosocial aspects play an important role in sexual
functioning. When discussing sexual functioning with
the patient, aforementioned issues should be considered
besides methadone dose [18, 29, 30].
Finally we wanted to explore whether ODAS is a useful
tool for identifying the ‘right’ methadone dose. From a
methodological viewpoint, an observational study without
control group does not deliver hard facts, but indices,
which may or may not lead to the proposal of a controlled
clinical study. When summarizing the findings, that a)
ODAS scores improved, b) daily doses of methadone in-
creased, whilst c) frequencies of sub-therapeutic doses
(<40 mg/day) decreased, and d) treatment proved to
be successful according to core outcome parameters
(EuropASI), one can conclude, that opioid maintenance
treatment is effective and adequate dosing can further
improve these effects. On the background of the German
(legal) treatment framework with its inherent abstinence
orientation, ODAS may serve as an instrument, which
provides standardized clinical parameters to guide dose ti-
tration. In the future, this hypothesis should be examined
in a controlled clinical trial.
Conclusion
Identification of an adequate methadone dose in opioid
substitution treatment is a frequent and difficult chal-
lenge in daily practice. Quarterly application of the
ODAS was associated with a clinically relevant increase
in adequately dosed patients. At the same time, addic-
tion severity decreased and sexual functioning improved
partially. Low-frequency use of ODAS in substitution
treatment may serve as useful approach to support ad-
equate methadone doses in substitution treatment.
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